加载中
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
前收盘价
US$30.82
−US$0.99 · -3.11%
盘中时间采用ET。市场数据可能有所延迟。
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
日内区间
当前US$30.82
52周区间
当前US$30.82
盘中时间采用ET。市场数据可能有所延迟。
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
日内区间
当前US$30.82
52周区间
当前US$30.82
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 5402.8万 USD | 3649.8万 USD | 2682.3万 USD | 1424万 USD | — |
| 销货成本 | 1152.2万 USD | 416.5万 USD | 950.4万 USD | 170.4万 USD | 1877.7万 USD |
| 毛利 | 4250.6万 USD | 3233.3万 USD | 1731.9万 USD | 1253.6万 USD | −1877.7万 USD |
| 研究与开发 | 3.34亿 USD | 3.01亿 USD | 2.89亿 USD | 2.8亿 USD | 2.57亿 USD |
| 销售、一般及管理费用 | 1.8亿 USD | 1.57亿 USD | 1.2亿 USD | 1.22亿 USD | 1.21亿 USD |
| 营业费用 | 5.15亿 USD | 4.58亿 USD | 4.09亿 USD | 4.02亿 USD | 3.6亿 USD |
| 利息收入 | 5637.9万 USD | 4808.3万 USD | 3334.4万 USD | 1279.3万 USD | 83.6万 USD |
| 折旧和摊销 | 517.7万 USD | 565.3万 USD | 662.3万 USD | 856.4万 USD | 924万 USD |
| 营业利润 | −4.72亿 USD | −4.26亿 USD | −3.91亿 USD | −3.89亿 USD | −3.78亿 USD |
| 净利润 | −4.13亿 USD | 6.74亿 USD | −3.52亿 USD | −2.32亿 USD | 16.05亿 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI6384.47万0.00%2.3万亿 USD0.03%US$381.57-0.10%
State Street SPDR S&P Biotech ETFXBI5335.21万0.54%103.03亿 USD0.35%US$151.4-1.54%
iShares Russell 2000 ETFIWM4902.52万0.06%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Morningstar Small-Cap ETFVB4606.46万0.02%1853亿 USD0.03%US$288.16-0.46%
Vanguard Morningstar Small-Cap Growth ETFVBK2638.55万0.06%447亿 USD0.05%US$340.88-1.12%
Vanguard Extended Market ETFVXF2327.92万0.02%954亿 USD0.05%US$233.52-0.63%
iShares Biotechnology ETFIBB1439.04万0.13%108.2亿 USD0.44%US$204.26-1.08%
Dimensional - US Small Cap ETFDFAS1426.46万0.04%338.04亿 USD0.31%US$78.17-0.23%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBDimensional - US Small Cap ETFDFASAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
